Search

Author/Creator Dijkstra, G

2. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitisAn unusual case of ascites. Issue 4 (7th November 2007)

Authors:
Wapenaar, M C; Monsuur, A J; van Bodegraven, A A; Weersma, R K; Bevova, M R; Linskens, R K; Howdle, P; Holmes, G; Mulder, C J; Dijkstra, G; van Heel, D A; Wijmenga, C
Journal:
Gut
Issue:
Volume 57:Issue 4(2008)
Page Start:
463
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. DOP036 Ustekinumab for Crohn's disease: a nationwide real-life observational cohort study (ICC case series). (16th January 2018)

Authors:
Biemans, V; van der Meulen - de Jong, A; van der Woude, C; de Boer, N; Dijkstra, G; Oldenburg, B; Ponsioen, C; Maljaars, P; Haans, J; Pierik, M; Hoentjen, F
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S055
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. DOP052 Vedolizumab vs. ustekinumab for Crohn's disease: comparative effectiveness in a real-life observational cohort study (ICC case series). (16th January 2018)

Authors:
Biemans, V; van der Woude, C; van der Meulen - de Jong, A; Dijkstra, G; de Boer, N; Oldenburg, B; Ponsioen, C; de Vries, A; Wintjens, D; Hoentjen, F; Pierik, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 12:Number 1(2018:Jan.)Supplement 1
Page Start:
S066
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy. (21st January 2022)

Authors:
Gabriëls, R Y; Linssen, M; van der Waaij, A; Volkmer, P; Hooghiemstra, W; Kats-Ugurlu, G; Robinson, D; Dijkstra, G; Nagengast, W
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i064
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. DOP24 Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesis. (25th January 2019)

Authors:
Weder, B; Van Haaften, W T; Baebler, K; Rogler, G; Dijkstra, G; Imenez Silva, P H; Wang, Y; De Vallière, C; Wagner, C; Frey-Wagner, I; Seuwen, K; Ruiz, P; Hausmann, M
Journal:
Journal of Crohn's and colitis
Issue:
Volume 13(2019)Supplement 1
Page Start:
S039
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. DOP46 Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel Disease. (30th January 2023)

Authors:
Bourgonje, A; Hu, S; Gacesa, R; Jansen, B H; Björk, J R; Bangma, A; Hidding, I J; van Dullemen, H M; Visschedijk, M C; Faber, K N; Dijkstra, G; Harmsen, H J M; Festen, E A M; Vich Vila, A; Spekhorst, L M; Weersma, R K
Journal:
Journal of Crohn's and colitis
Issue:
Volume 17(2023)Supplement 1
Page Start:
i113
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. DOP53 In-depth characterisation of the serum antibody epitope repertoire in Inflammatory Bowel Disease by high-throughput phage-displayed immunoprecipitation sequencing. (21st January 2022)

Authors:
Bourgonje, A R; Andreu-Sánchez, S; Vogl, T; Hu, S; Vich Vila, A; Leviatan, S; Kurilshikov, A; Klompus, S; Kalka, I N; van Dullemen, H M; Weinberger, A; Visschedijk, M C; Festen, E A M; Faber, K N; Wijmenga, C; Dijkstra, G; Segal, E; Fu, J; Zhernakova, A; Weersma, R K
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i100
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. DOP58 Tofacitinib for ulcerative colitis: Results of the ICC Registry, a nationwide prospective observational cohort study. (15th January 2020)

Authors:
Biemans, V B; Sleutjes, J A M; de Vries, A C; Bodelier, A G; Dijkstra, G; Oldenburg, B; Löwenberg, M; van Bodegraven, A A; van der Meulen-de Jong, A E; de Boer, N K; Srivastava, N; West, R L; Römkens, T; Horjus Talabur Horje, C S; Jansen, J M; Hoekstra, J; Weersma, R K; van Schaik, F D; Hoentjen,...
Journal:
Journal of Crohn's and colitis
Issue:
Volume 14(2020)Supplement 1
Page Start:
S097
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease. (21st January 2022)

Authors:
Volkers, A; Straatmijer, T; Duijvestein, M; Sales, A; Levran, A; van Schaik, F; Jeroen, M; Gecse, K; Ponsioen, C; Grootjans, J; Hanzel, J; Tack, G; Jansen, J; Hoentjen, F; de Boer, N; van der Marel, S; Dijkstra, G; Oldenburg, B; Löwenberg, M; van der meulen, A
Journal:
Journal of Crohn's and colitis
Issue:
Volume 16(2022)Supplement 1
Page Start:
i108
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗